Tainan, Taiwan, February 13, 2026 — Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company” or “Advanced Biomed”), a biotechnology firm focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced it has entered into a clinical research collaboration agreement (the “Agreement”) with Chi-Mei Medical Center to launch a 120-case feasibility study. The study is designed to evaluate the predictive accuracy of the Company’s A+PerfusC™, a perfusion-based 3D cell culture system in a compact incubator engineered to replicate human physiological conditions in vitro.
This feasibility study is a non-interventional clinical research project that has received Institutional Review Board approval. Case collection began in early February 2026 at Chi-Mei Medical Center, with interim comparative data expected between May and June 2026 and full study completion targeted by the end of 2026. The study will compare ex-vivo drug sensitivity results generated by the A+PerfusC platform (from circulating tumor cells obtained via liquid biopsy) with actual patient clinical outcomes to assess correlation and predictive performance. It follows the Company’s September 2025 commercial launch of the A+PerfusC integrated perfusion 3D cell culture platform and represents an additional way to translate the system’s laboratory strengths into evidence applicable to clinical practice.
This collaboration is significant because it aims to address a core limitation of current preclinical and guideline-driven approaches to oncology treatment selection. Two-dimensional cell culture models and xenograft animal models often fail to recapitulate the complex, patient-specific biology of human tumors and are constrained by low throughput and long turnaround times. By contrast, the A+PerfusC platform isolates high-viability circulating tumor cells using label-free microfluidic technology and grows them in automated 3D culture arrays that enable parallel testing of multiple drugs and combinations. This functional, patient-derived testing approach seeks to shorten the time to an evidence-based treatment decision, reduce exposure to ineffective therapies and their toxicities, and provide clinicians with a practical tool to prioritize therapies most likely to benefit individual patients.
Beyond direct patient impact, the platform also addresses practical and ethical constraints associated with animal-based models. Replacing large cohorts of mice with high-density arrays of patient-derived tumor spheroids enables high-throughput screening that is not feasible with xenografts, while Advanced Biomed’s automated A+PerfusCTM system is intended to reduce labor intensity and scale functional testing to clinically actionable timeframes. The Company expects the feasibility study’s results to inform the design of subsequent, larger clinical validation studies and to support its use as a predictive tool for treatment response and Clinical Decision Support (CDS), pending favorable outcomes and regulatory review.
“We believe the A+PerfusC platform can materially improve how oncologists select therapies by delivering patient-specific, functional drug sensitivity data derived from a minimally invasive liquid biopsy,” said Dr. Yi Lu, Chief Executive Officer of Advanced Biomed. “This feasibility study with Chi-Mei Medical Center is a critical step toward demonstrating the platform’s real-world predictive value and advancing precision oncology beyond genomic inference to functional, individualized testing.”
Advanced Biomed and Chi-Mei Medical Center will jointly conduct the non-commercial clinical research and collaborate on subsequent commercial development. Under the Agreement, both parties will share rights to project-related intellectual property and research outcomes.
About Advanced Biomed Inc.
Advanced Biomed Inc. is a Nevada corporation specializing in innovative biomedical technologies for cancer detection and precision medicine.
Operating through its subsidiary in Taiwan, the Company has developed a proprietary microfluidic platform that integrates semiconductor and biotechnology to enable advanced circulating tumor cell (CTC) detection, enrichment, and analysis. Its portfolio includes devices, biochips, and designed for cancer screening, diagnosis, treatment selection, and prognosis assessment, with regulatory clearances in progress in Taiwan and plans for future global expansion.
For more information, please visit: .
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are not historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, uncertainties related to market conditions and other factors discussed in documents filed with the United States Securities and Exchange Commission (the “SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at . The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
Advanced Biomed Inc.
Steven I-Fang Cheng
Email:
